Scarica l'app Stockscreener
0.395
1.20%
-0.0048
Dopo l'orario di chiusura:
.40
0.005
+1.27%
Precedente Chiudi:
$0.3998
Aprire:
$0.41
Volume 24 ore:
173.06K
Relative Volume:
0.01
Capitalizzazione di mercato:
$7.69M
Reddito:
$4.71M
Utile/perdita netta:
$-11.79M
Rapporto P/E:
-0.1179
EPS:
-3.3492
Flusso di cassa netto:
$-9.72M
1 W Prestazione:
-4.20%
1M Prestazione:
-10.79%
6M Prestazione:
-35.20%
1 anno Prestazione:
-83.88%
Intervallo 1D:
$0.393
$0.4266
Intervallo di 1 settimana:
$0.393
$0.4289
Portata 52W:
$0.23
$2.75
Ensysce Biosciences Inc Stock (ENSC) Company Profile
Nome
Ensysce Biosciences Inc
Settore
Industria
Telefono
(858) 263-4196
Indirizzo
7946 IVANHOE AVENUE, LA JOLLA
Compare ENSC vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ENSC
Ensysce Biosciences Inc
|
0.395 | 8.02M | 4.71M | -11.79M | -9.72M | -3.3492 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ensysce Biosciences Inc Borsa (ENSC) Ultime notizie
ENSC Forecast — Price Target — Prediction for 2027 - TradingView
Ensysce Biosciences Updates Series C Preferred Stock Terms - TipRanks
Energy Focus, Inc. (EFOI) Latest Stock News & HeadlinesYahoo Finance - Yahoo! Finance Canada
Ensysce Biosciences, Inc. (ENSC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Ensysce Biosciences, Inc. (ENSC) Latest Stock News & Headlines - Yahoo! Finance Canada
Ensysce submits Phase 2a protocol for CRPS treatment CY200 - Investing.com
Ensysce submits Phase 2a protocol for CRPS treatment CY200 By Investing.com - Investing.com UK
Ensysce Biosciences Phase 2 Protocol for CY200A Neuroplastigen for the Treatment of CRPSSubmitted to the UK MHRA - Corsicana Daily Sun
A study plan for a pain condition with no treatment that cures it reaches UK regulators. - Stock Titan
ENSC News | ENSYSCE BIOSCIENCES INC (NASDAQ:ENSC) - ChartMill
Ensysce hosts symposium at PainWeek, attends FDA hearing By Investing.com - Investing.com Canada
Ensysce hosts symposium at PainWeek, attends FDA hearing - Investing.com
Ensysce Biosciences Advances CRPS Program at Painweek 2026, Contributes to FDA Hearing on Psychedelic Drug Regulation - Corsicana Daily Sun
More than 320 pain professionals attended Ensysce’s symposium on complex pain. - Stock Titan
Ensysce Biosciences Inc (NASDAQ: ENSC) Share Price, ENSC Stock News, ENSC Share Price & Updates - kalkine.com.au
A doctor from Ensysce is among a limited group chosen to speak at an FDA psychedelic hearing - Stock Titan
Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs - Corsicana Daily Sun
ORCL: Oracle Corp. Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
ENSC Q2 2026 Earnings: 60.78% EPS Beat Buys Optionality as Pre-Revenue Pipeline AdvancesEarnings Yield Analysis - dars.gov.et
An FDA hearing on psychedelic drugs is set for Sept. 14. Ensysce will take part. - Stock Titan
Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation - Yahoo Finance
Ensysce completes PF614-MPAR-102 clinical enrollment - grafa.com
Ensysce completes enrollment in opioid overdose study By Investing.com - Investing.com Australia
Ensysce completes enrollment in opioid overdose study - Investing.com India
An opioid study from Ensysce is fully enrolled to test overdose protection - stocktitan.net
Ensysce Faces Nasdaq Delisting Risk After Cy Biopharma Deal Triggers Change of Control - minichart.com.sg
Ensysce Biosciences Seeks Extended Nasdaq Compliance Grace Period - The Globe and Mail
Ensysce Biosciences raises $21M in initial tranche, meets Nasdaq equity rules, seeks second bid-price grace period - TradingView
Ensysce (ENSC) completes private raise with contingent proceeds - Stock Titan
Ensysce (ENSC) Results Versus Estimates: The Bottom-Line Figure Beats Its Comparison in the Latest Reading; After Earnings: The Stock Ends Down 3.87% for the Current SessionEarnings Yield Spread - vinanet.vn
Ensysce (ENSC) chair boosts stake, locks in votes on merger - Stock Titan
ENSC: Acquisition and financing position CY200 for CRPS advancement, extending cash runway to 2027 - TradingView
ENSC: Acquisition and financing position CY200 for Phase II CRPS trial and long-term pipeline growth - TradingView
Ensysce Biosciences director Gower buys $444,169 in company stock - Investing.com
Ensysce Biosciences Insider Bought Shares Worth $444,169, According to a Recent SEC Filing - marketscreener.com
Ensysce Biosciences (ENSC) director buys stock and converts debt - Stock Titan
Ensysce Biosciences earnings beat by $0.51, revenue fell short of estimates - Investing.com Canada
MSN Money - MSN
Daily Brief Health Care: Modern Dental Group, Suzhou Zelgen Biopharmaceuticals, Blue Water Vaccines, Ono Pharmaceutical, Ensysce Biosciences , Dyadic International , Atossa Therapeutics and more - Smartkarma
Ensysce Completes Cy Biopharma Acquisition Adding Lead CRPS Candidate - Minichart
Form 8K Ensysce Biosciences Inc For: 13 August By Investing.com - Investing.com Australia
Ensysce Q2 EPS beats; completes Cy Biopharma acquisition for $38.6m - scanx.trade
Ensysce Biosciences (ENSC) widens loss as cash falls, adds funding via Cy Biopharma deal - Stock Titan
Ensysce Biosciences Q2 net loss widens on higher R&D costs - TradingView
ENSC: Acquisition and new funding extend cash runway, with clinical pipeline and losses both increasing - TradingView
Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights - FinancialContent
ENSC Q1 2026 Earnings: Narrower-than-Expected Loss Marks 30% Beat Amid Persistent Share Weakness - vinanet.vn
Cy Biopharma merges with Ensysce Biosciences - Startupticker.ch
Ensysce Biosciences (ENSC) officer reports 154.8M underlying common via preferred - Stock Titan
Ensysce Biosciences Inc Azioni (ENSC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ensysce Biosciences Inc Azioni (ENSC) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| GOWER BOB G | Director |
Aug 07 '26 |
Buy |
0.49 |
400,000 |
198,000 |
916,740 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):